A comparative safety review of targeted therapies for acute myeloid leukemia

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi: 10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.
   PubMed Web of Science ®Google Scholar
• Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol. 2019;85(12):2689–2693. doi: 10.1111/bcp.14105
   PubMed Web of Science ®Google Scholar
• Caravatti G, Meyer T, Fredenhagen A, et al. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Bioorg Med Chem Lett. 1994;4(3):399–404.
   Web of Science ®Google Scholar
• Rüegg UT, Gillian BG. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci. 1989;10(6):218–220. doi: 10.1016/0165-6147(89)90263-0
   PubMed Web of Science ®Google Scholar
• Eder JP Jr, Garcia-Carbonero R, Clark JW, et al. A phase I trial of daily oral 4’- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs. 2004;22(2):139–50. doi: 10.1023/B:DRUG.0000011790.31292.ef
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443. doi: 10.1016/s1535-6108(02)00069-7
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339–4345.
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061–2068. doi: 10.1038/leu.2012.115
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi: 10.1056/NEJMoa1614359
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: Midostaurin prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Mar 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
   Google Scholar
• Vaidya P, Khedro T, Yaghmour B, et al. Midostaurin-Related Interstitial Lung Injury in FLT3+ Acute Myeloid Leukemia Post-Allogeneic Transplant. World J Oncol. 2019;10(6):237–239. doi: 10.14740/wjon1232
   PubMedGoogle Scholar
• Nuhoğlu Kantarcı E, Eşkazan AE. Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions. Leukemia Research. 2022;114:106808. doi: 10.1016/j.leukres.2022.106808
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335. doi: 10.1182/blood.v99.12.4326
   PubMed Web of Science ®Google Scholar
• Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013(1):220–226. doi: 10.1182/asheducation-2013.1.220
   PubMedGoogle Scholar
• Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556–565. doi: 10.1007/s10637-017-0470-z
   PubMed Web of Science ®Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi: 10.1056/NEJMoa1902688
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: Gilteritinib prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Mar 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf
   Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi: 10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478–493.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731. doi: 10.1182/blood-2017-04-779405
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: enasidenib prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Mar 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf
   Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi: 10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi: 10.1056/NEJMoa1716984
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471. doi: 10.1182/blood.2019002140
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: ivosidenib prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Mar 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf
   Google Scholar
• Salifu EY, Agoni C, Soliman MES. Highlighting the mechanistic role of olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (MIDH1) in Cancer therapy. IMU. 2022;28:100829. doi: 10.1016/j.imu.2021.100829
   Google Scholar
• Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10(1):e46–e58. doi: 10.1016/S2352-3026(22)00292-7
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: olutasidenib prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Apr 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf
   Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341. doi: 10.1016/j.stem.2012.12.013
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81(11):3091–3096.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi: 10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32(2):303–312. doi: 10.1038/leu.2017.243
   PubMed Web of Science ®Google Scholar
• Jin S, Cojocari D, Purkal JJ, et al. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clin Cancer Res. 2020;26(13):3371–3383.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi: 10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: venetoclax prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Apr 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208573s027lbl.pdf
   Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–629. doi: 10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi: 10.1182/blood.2020004856
   PubMed Web of Science ®Google Scholar
• Maiti A, Konopleva MY. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia. Cancer J. 2022;28(1):2–13. doi: 10.1097/PPO.0000000000000567
   PubMed Web of Science ®Google Scholar
• Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119(10):2196–2204. doi: 10.1182/blood-2011-10-383752
   PubMed Web of Science ®Google Scholar
• Bai LY, Chiu CF, Lin CW, et al. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Leukemia. 2008;22(1):226–228. doi: 10.1038/sj.leu.2404978
   PubMed Web of Science ®Google Scholar
• Chahal KK, Parle M, Abagyan R. Hedgehog pathway and smoothened inhibitors in cancer therapies. Anticancer Drugs. 2018;29(5):387–401. doi: 10.1097/CAD.0000000000000609
   PubMed Web of Science ®Google Scholar
• Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107(10):1422–1429.
   PubMed Web of Science ®Google Scholar
• Savona MR, Pollyea DA, Stock W, et al. Phase ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res. 2018;24(10):2294–2303.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389. doi: 10.1038/s41375-018-0312-9
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: glasdegib prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Apr 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210656s005lbl.pdf
   Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863.
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129–139.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246. doi: 10.1182/blood-2013-12-540971
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi: 10.1200/JCO.2017.77.6112
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: CPX-351 prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2023 Apr 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209401s006lbl.pdf
   Google Scholar
• Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi: 10.1136/heartjnl-2017-312103
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Gorcsan J, Boehmer J, et al. Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia. J Clin Oncol. 2023;41(suppl 16; abstr7029):7029.
   Google Scholar
• Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016;7(1):87–97. doi: 10.5306/wjco.v7.i1.87
   PubMedGoogle Scholar
• Fostvedt LK, Hibma JE, Masters JC, et al. Pharmacokinetic/Pharmacodynamic modeling to support the re-approval of Gemtuzumab Ozogamicin. Clin Pharmacol Ther. 2019;106(5):1006–1017.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130(22):2373–2376. doi: 10.1182/blood-2017-09-797712
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–1452. doi: 10.1002/cncr.21326
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860. doi: 10.1182/blood-2013-01-466706
   PubMed Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71. doi: 10.1038/sj.leu.2404434
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9. doi: 10.1200/JCO.2015.64.0060
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: Gemtuzumab ozogamicin prescribing information. [Internet]. Silver Spring (MD): Food and Drug Administration;[cited 2023 Apr 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf
   Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukemia (ALFA-0701): a randomized, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16. doi: 10.1016/S0140-6736(12)60485-1
   PubMed Web of Science ®Google Scholar
• Cortes JE, de Lima M, Dombret H, et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):137. doi: 10.1186/s13045-020-00975-2
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Fiedler W, et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020;13(1):92.
   PubMed Web of Science ®Google Scholar